Protease Inhibitors: all 1,856 studies that test it

Page 9 of 19. Open to participants first (69), then studies with results posted, then the rest; newest registration first within each.

• Evaluate the Efficacy and Safety of FB2001 in Hospitalized Patients With Moderate to Severe COVID-19 (BRIGHT Study)Status unknownNCT05445934Phase 2/3
• Exploratory Study of Aerosol Inhalation of FB2001 for Post-exposure Prophylaxis of COVID-19 Close ContactsStatus unknownNCT05415241Phase 1/2
• Clinical Efficacy of Ulinastatin for Treatment of Sepsis With Systemic Inflammatory Response SyndromeCompletedNCT05391789Phase 3
• A Study to Assess the Safety and Pharmacokinetics of Single Ascending Subcutaneous and Intravenous Doses of DS-2325a in Healthy SubjectsCompletedNCT05388903Phase 1
• A Study to Learn About the Study Medicine (Nirmatrelvir Plus Ritonavir) in Pregnant Women With COVID-19TerminatedNCT05386472Phase 1
• Paxlovid in the Treatment of COVID-19 Patients With UremiaStatus unknownNCT05386433Early Phase 1
• A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Compared to the Co-administration of the Separate Available Formulations of Darunavir and Cobicistat Under Fed Conditions in Healthy ParticipantsCompletedNCT05378906Phase 1
• Evaluation of SSD8432 and Ritonavir in Adult Subjects With COVID-19 Clinical StudyStatus unknownNCT05373446Phase 2
• To Evaluate SSD8432/Ritonavir in Adults With COVID-19Status unknownNCT05373433Phase 2/3
• Improvement of Pulmonary Insufficiency After Aortic Dissection With Sivelestat SodiumStatus unknownNCT05343338Not applicable
• A Phase I Clinical Study of SSD8432 in Healthy Adult SubjectsStatus unknownNCT05339646Phase 1
• Intra-lesional ACE Inhibitor for Treatment of Hypertrophic ScarsWithdrawnNCT05259137Phase 2/3
• A Study to Compare the Drug Levels of Atazanavir and Cobicistat Between the Coadministration of Age-Appropriate Mini-Tablet Formulations and the Coadministration of the Individual Reference Products in Healthy Adults Under Fed ConditionsCompletedNCT05236738Phase 1
• Once Daily Dosing of Lonafarnib Co-administered With Ritonavir for Treatment of Chronic Hepatitis D Virus InfectionCompletedNCT05229991Phase 3
• Anti-Secretory Drug in Treatment of Acute Watery DiarrheaCompletedNCT05216822Phase 1
• A Bridging Study of FB2001 in Healthy SubjectsCompletedNCT05197179Phase 1
• Study to Investigate the Mass Balance, Metabolism, and Excretion of [14C]PF-07321332 in Healthy Male Participants.WithdrawnNCT05178654Phase 1
• Impact of Obesity on the Pharmacokinetics of Imipenem-Relebactam in ICU PatientsWithdrawnNCT05146154Phase 4
• Recombinant Human C1 Esterase Inhibitor (Conestat Alfa) in the Prevention of Acute Ischemic Cerebral and Renal Events After Transcatheter Aortic Valve ImplantationCompletedNCT05145283Phase 2
• Providing PrEP, Hepatitis C Treatment, and MOUD Through Telemedicine at Greensboro SSPCompletedNCT05108935Not applicable
• Public Health Emergency: SOLIDARITY TRIAL PhilippinesCompletedNCT05024006Not applicable
• Study of PBI-0451 in Healthy Subjects.CompletedNCT05011812Phase 1
• A Multi-center Open-label Phase 2 Study of Ixazomib, Iberdomide and Dexamethasone in Elderly Patients With Multiple Myeloma at First Relapse."Active, not recruitingNCT04998786Phase 2
• AL101 Before Surgery for the Treatment of Notch Activated Adenoid Cystic CancerCompletedNCT04973683Phase 1
• Protective Effect of Sivelestat Sodium on ARDS in Patients With SepsisStatus unknownNCT04973670Phase 3
• Treatment of ARDS With Sivelestat SodiumCompletedNCT04909697Phase 4
• 8- Versus 12-week of Sofosbuvir-ravidasvir Treatment of Chronic Hepatitis CCompletedNCT04885855Phase 2/3
• Comparing the Efficacy of Anti-secretory Versus Oral Immunoglobulins for Reducing the Episodes of Diarrhea in ChildrenStatus unknownNCT04885049Not applicable
• A Study of AL102 in Patients With Progressing Desmoid TumorsActive, not recruitingNCT04871282Phase 2/3
• Venetoclax, MLN9708 (Ixazomib Citrate) and Dexamethasone for the Treatment of Relapsed or Refractory Light Chain AmyloidosisActive, not recruitingNCT04847453Phase 1
• PK, PD, Tolerability and Safety of MDPK67b in Healthy VolunteersCompletedNCT04839120Phase 1
• Safety and Pharmacokinetics Evaluation Study According to the Dose of Camostat Mesylate in Healthy VolunteersCompletedNCT04782505Phase 1
• Comparative Therapeutic Efficacy and Safety of Different Antiviral and Anti Inflammatory Drugs in COVID-19 Patients.Status unknownNCT04779047Phase 4
• The Safety and Efficacy of FB2001 in Healthy Subjects and Patients With COVID-19 InfectionCompletedNCT04766931Phase 1
• Efficacy and Safety of Colistin Based Antibiotic TherapyStatus unknownNCT04764058Phase 1/2
• Safety and Preliminary Efficacy of the Combination of Niclosamide and CamostatTerminatedNCT04750759Phase 2
• The DAWN Antivirals Trial for Ambulatory COVID-19 PatientsTerminatedNCT04730206Phase 3
• A Study of DWJ1248 in Prevention of COVID-19 Infection After the Exposure of SARS-COV-2TerminatedNCT04721535Phase 3
• A Study of Darunavir in the Presence of Cobicistat When Administered as a Fixed Dose Combination Under Fed ConditionsCompletedNCT04718805Phase 1
• Efficacy and Safety of DWJ1248 With Remdesivir in Severe COVID-19 PatientsTerminatedNCT04713176Phase 3
• Protective Effect of Ulinastatin Against Negative Inflammatory Response and Organ Dysfunction After Acute Type a Aortic Dissection Surgery (PANDA I)CompletedNCT04711889Not applicable
• Study to Evaluate the Benefit of RUCONEST in Improving Neurological Symptoms in Post COVID-19 InfectionCompletedNCT04705831Phase 2
• A Single-center Pilot Study Evaluating a Preemptive Short Course of Glecaprevir/Pibrentasvir in Hepatitis C Positive to Negative Kidney TransplantationCompletedNCT04682509Early Phase 1
• Reconvalescent Plasma/Camostat Mesylate Early in SARS-CoV-2 Q-PCR (COVID-19) Positive High-risk IndividualsCompletedNCT04681430Phase 2
• Aralast NP With Antiviral Treatment and Standard of Care Versus Antiviral Treatment With Standard of Care in Hospitalized Patients With Pneumonia and COVID-19 InfectionWithdrawnNCT04675086Phase 3
• A Study in Healthy Participants to Assess the Effect of Darunavir, Emtricitabine, and Tenofovir Alafenamide in the Presence of Cobicistat as Fixed Dose Combination (Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide) Compared With Co-administration of the Separate AgentsCompletedNCT04661397Phase 1
• A Study of FOY-305 in Patients With SARS-Cov-2 Infection (COVID-19)CompletedNCT04657497Phase 3
• Single Ascending Dose Study of Intravenous Infusion of PF 07304814 in Healthy Adult ParticipantsCompletedNCT04627532Phase 1
• Single Patient Protocol for Donor HCV-positive to Recipient HCV-negative Kidney Transplant in a Patient at Risk for Loss of Dialysis AccessWithdrawnNCT04614142Phase 4
• CAMOVID : Evaluation of Efficacy and Safety of Camostat Mesylate for the Treatment of SARS-CoV-2 Infection - COVID-19 in Ambulatory Adult PatientsTerminatedNCT04608266Phase 3
• Prevention of Transmission of Hepatitis C Virus (HCV) From HCV-Viremic Organ DonorCompletedNCT04596475Phase 1/2
• COVID-19 Prophylaxis South Africa (COVER HCW)CompletedNCT04561063Phase 2
• GLS4/RTV and TAF Drug-drug InteractionCompletedNCT04551261Phase 1
• A Study of the Pharmacokinetics of ASC09F in Healthy SubjectsCompletedNCT04547894Phase 1
• HepATocellular Cancer Hcv Therapy StudyWithdrawnNCT04546802Phase 3
• An Open Non-comparative Study of the Efficacy and Safety of Aprotinin in Patients Hospitalized With COVID-19Status unknownNCT04527133Not applicable
• A Study to Evaluate Preemptive Therapy in Hepatitis C (HCV) Organ Transplant RecipientsActive, not recruitingNCT04508907Phase 4
• ACTIV-3: Therapeutics for Inpatients With COVID-19CompletedNCT04501978Phase 3
• FLARE: Favipiravir +/- Lopinavir: A RCT of Early AntiviralsCompletedNCT04499677Phase 2
• Study of Continuous APL-1202 Treatment in Subjects With High-Risk Non-Muscle-Invasive Bladder Cancer (NMIBC) Relapsed From Intravesical Chemo/BCG TherapyCompletedNCT04498702Phase 2
• Study to Evaluate the Safety and Efficacy of Prolastin in Hospitalized Subjects With COVID-19CompletedNCT04495101Phase 2
• Australasian COVID-19 Trial (ASCOT) ADAptive Platform TrialActive, not recruitingNCT04483960Phase 3
• Antiviral Agents Against COVID-19 InfectionCompletedNCT04468087Phase 2/3
• Zanubrutinib, Ixazomib and Dexamethasone in Patients With Treatment Naive Waldenstrom's MacroglobulinemiaCompletedNCT04463953Phase 2
• A Study of Combination Therapies to Treat COVID-19 InfectionWithdrawnNCT04459702Phase 2
• The Nitazoxanide Plus Atazanavir for COVID-19 StudyTerminatedNCT04459286Phase 2
• Lopinavir/Ritonavir for the Treatment of COVID-19 Positive Patients With Cancer and Immune Suppression in the Last YearWithdrawnNCT04455958Phase 2
• Multiple-dose Study of FOY-305 in Japanese Healthy Adult Male SubjectsCompletedNCT04451083Phase 1
• Efficacy and Safety of Anti HCV Drugs in the Treatment of COVID-19Status unknownNCT04443725Phase 2/3
• ARALAST NP Alpha-1 Lung Density Chronic Obstructive Pulmonary Disease-Emphysema (COPD-E) StudyWithdrawnNCT04440488Phase 4
• The Utility of Camostat Mesylate in Patients With COVID-19 Associated Coagulopathy (CAC) and Cardiovascular ComplicationsWithdrawnNCT04435015Phase 1/2
• Conestat Alfa in the Prevention of Severe SARS-CoV-2 Infection in Hospitalized Patients With COVID-19TerminatedNCT04414631Phase 2
• Evaluation of Additional Treatments for COVID-19: a Randomized Trial in NigerWithdrawnNCT04409483Phase 3
• Hydroxychloroquine and Lopinavir/ Ritonavir to Improve the Health of People With COVID-19: "The Hope Coalition - 1"Status unknownNCT04403100Phase 3
• Ultra Low Doses of Therapy With Radiation Applicated to COVID-19SuspendedNCT04394182Not applicable
• Ulinastatin for the Treatment of COVID-19 in Hospitalized PatientsWithdrawnNCT04393311Phase 1/2
• Sofosbuvir/Ombitasvir/Paritaprevir/ Ritonavir and Ribavirin for Hepatitis C Virus Genotype 4 PatientsCompletedNCT04391985Phase 1/2
• Rapid Reinitiation of a Single Tablet Antiretroviral Therapy Using Symtuza® in HIV-1 Infected Treatment-Experienced Patients Off Therapy. (ReSTART)CompletedNCT04388904Phase 4
• Bioequivalence Study of Lopinavir/Ritonavir 200/50 mg Film Tablet (World Medicine Ilac, Turkey) Under Fasting ConditionsCompletedNCT04386876Phase 1
• Sofosbuvir With Ribavirin or Simeprevir With HCV GT4 Egyptian PatientsCompletedNCT04385407Phase 2
• OUTpatient Treatment of COVID-19 in Patients With Risk Factor for Poor OutcomeWithdrawnNCT04365582Phase 3
• Efficacy of Pragmatic Same-day COVID-19 Ring Prophylaxis for Adult Individuals Exposed to SARS-CoV-2 in SwitzerlandCompletedNCT04364022Phase 3
• A Study of the Relative Bioavailability of ASC18 Tablets vs Reference Tablets in Healthy VolunteersCompletedNCT04358523Phase 1
• Austrian CoronaVirus Adaptive Clinical Trial (COVID-19)Status unknownNCT04351724Phase 2/3
• A Single Dose Safety, Tolerability, Pharmacokinetic and Food Effect Study of KVD900 (Sebetralstat) in Healthy VolunteersCompletedNCT04349800Phase 1
• Efficacy and Safety of Ganovo (Danoprevir) Combined With Ritonavir in the Treatment of SARS-CoV-2 InfectionCompletedNCT04345276Phase 4
• Combination Therapy With Camostat Mesilate + Hydroxychloroquine for COVID-19WithdrawnNCT04338906Phase 4
• Chemoprophylaxis of SARS-CoV-2 Infection (COVID-19) in Exposed Healthcare WorkersTerminatedNCT04328285Phase 3
• COVID-19 Ring-based Prevention Trial With Lopinavir/RitonavirStatus unknownNCT04321174Phase 3
• The Impact of Camostat Mesilate on COVID-19 InfectionCompletedNCT04321096Phase 1/2
• Bioequivalence Study for Fixed Dose Combination Zemimet® SR Tab. 50/1000 and Coadministration of Gemigliptin 50 mg and Metformin 1000 mg.CompletedNCT04317703Phase 1
• Trial of Treatments for COVID-19 in Hospitalized AdultsCompletedNCT04315948Phase 3
• Comparison of Lopinavir/Ritonavir or Hydroxychloroquine in Patients With Mild Coronavirus Disease (COVID-19)TerminatedNCT04307693Phase 2
• A Study to Examine the Acceptable Taste and to Estimate the Amount of Atazanavir and Cobicistat in the Body When Taken as a Combination Product Versus When Taken as Separate Products at the Same TimeCompletedNCT04263350Phase 1
• Evaluating and Comparing the Safety and Efficiency of ASC09/Ritonavir and Lopinavir/Ritonavir for Novel Coronavirus InfectionTerminatedNCT04261907Not applicable
• A Randomized,Open,Controlled Clinical Study to Evaluate the Efficacy of ASC09F and Ritonavir for 2019-nCoV PneumoniaStatus unknownNCT04261270Phase 3
• A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV PneumoniaStatus unknownNCT04255017Phase 4
• Comparative Effects of Perindopril and Zofenopril on Blood Pressure Control and Oxidative Status Blacks Hypertensive Patients.CompletedNCT04254042Phase 4
• The Efficacy of Lopinavir Plus Ritonavir and Arbidol Against Novel Coronavirus InfectionCompletedNCT04252885Phase 4
• Efficacy and Safety of Darunavir and Cobicistat for Treatment of COVID-19Status unknownNCT04252274Phase 3

← Protease Inhibitors overview